HUMIRA

Type: Product
Name: HUMIRA
First reported Aug 28 2014 - Updated Aug 28 2014 - 2 reports

AbbVie: Growth Story Or Patent Expiration Nightmare?

By Sure Dividend :AbbVie (NYSE: ABBV ) is a global biopharmaceutical company, with over 25,000 employees and products sold in over 170 countries. AbbVie split off from parent company Abbott Laboratories (NYSE: ABT ) in January of 2013. The company currently ... [Published BioPortfolio - Aug 28 2014]
First reported Aug 27 2014 - Updated Aug 27 2014 - 1 reports

Is It Time to Buy AbbVie Stock?

One month after two big announcements, the dust has settled somewhat for AbbVie ( NYSE: ABBV     ) . Those major announcements, of course, were a blow-out second quarter and the acquisition of Shire plc ( NASDAQ: SHPG     ) .In the first few days after ... [Published Motley Fool Discussion Boards - Aug 27 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 1 reports

Five things for pharma marketers to know: Monday, August 25

Share this article:Five things for pharma marketers to know: Monday August 25Roche is no longer looking to own Japanese drugmaker Chugai in full. Bloomberg reports that the Swiss company has decided not to scoop up the 38% of shares it does not already ... [Published Medical Marketing And Media - Aug 25 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 1 reports

Psoriatic arthritis outcomes worse with smoking

Share this article:Worse patient-reported outcomes, shorter treatment adherence, and poorer response to treatment among smokers.Psoriatic arthritis biologic treatment outcomes worsened by smokingPatients with psoriatic arthritis (PsA) who smoke are less ... [Published The Clinical Advisor - Aug 25 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 1 reports

Humira patent invalid for obviousness type double patenting

In the Federal Circuit affirmed the district court’s finding that a second patent covering AbbVie’s Humira product is invalid under the doctrine of obviousness-type double patenting. The decision reaffirms the court’s stance in Gilead that the doctrine ... [Published Lexology - Aug 25 2014]
First reported Aug 22 2014 - Updated Aug 22 2014 - 1 reports

Biotech comeback

By Wall, J K Proquest LLCIn the 1980s, Eli Lilly and Co. launched the world's first biotech drug and was one of the first big pharma companies to focus research on treating autoimmune diseases.Then, in the 1990s, Lilly abandoned both its biotech and autoimmune ... [Published Insurance News Net - Aug 22 2014]
First reported Aug 22 2014 - Updated Aug 22 2014 - 1 reports

Finnegan Beats Humira IP Licensing Claims for AbbVie

A U.K. arthritis research trust overreached by demanding more patent royalties from drugmaker and longtime licensee AbbVie, an appeals court ruled on Thursday. ... [Published Law.com - Newswire - Aug 22 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 1 reports

Get the right drug to treat psoriasis

Studies show that these medications are effective for relieving psoriasis and psoriatic arthritis symptoms in most people, and they also may have lower rates of side effects than some other biologics, such as infliximab (Remicade). People in several studies ... [Published Consumer Reports - Aug 20 2014]
Entities: Psoriasis, Enbrel, Stelara
First reported Aug 15 2014 - Updated Aug 15 2014 - 2 reports

Coherus Announces CHS-1420 (Investigational Adalimumab Biosimilar) Meets Primary Endpoint In

Coherus BioSciences, Inc. ("Coherus") today announced that CHS-1420, its proposed biosimilar of adalimumab (Humira(R)), met the primary endpoint in a pivotal clinical pharmacokinetic (PK) similarity study that compared CHS-1420 to Humira(R) in healthy ... [Published Newswit.com - Aug 15 2014]
First reported Aug 05 2014 - Updated Aug 05 2014 - 1 reports

Is AbbVie A Long-Term Buy?

Summary The acquisition of Shire would not only provide a tax advantage to AbbVie but would also help the company to grow its revenue base through portfolio expansion. Shire has reported a very strong performance in its latest reported quarter indicating ... [Published Seeking Alpha - Aug 05 2014]
First reported Aug 05 2014 - Updated Aug 05 2014 - 1 reports

3 Businesses That Stand To Lose With Budding Marijuana Acceptance

Summary 23 States have legalized medical cannabis, which can be used to treat a wide range of health issues. Cost cutting has lead states to rethink sentencing guidelines and in some cases offer early release, especially to those who committed certain ... [Published Seeking Alpha - Aug 05 2014]
First reported Aug 04 2014 - Updated Aug 05 2014 - 1 reports

Human medicines European public assessment report (EPAR): Humira, adalimumab, Revision: 35, Authorised

Entities: Adalimumab, HUMIRA, Humanism

Quotes

"The integration activity specifically resulted in some isolated challenges with some of our clients revamped our leadership, strongly aligned our metrics to key service indicators, and redefined our commitment to service across the organization" said Express Scripts President Tim Wentworth
And there is potentially a looming brick wall ahead: loss of patent exclusivity for Humira in 2016. Novartis " Sandoz business unit began a phase 3 study of a biosimilar of Humira last December. Should this study prove successful, Humira sales could be hit hard."
...an increasing percentage of insurance spending for prescription medications," said Kev Coleman , Head of Research & Data at HealthPocket , "and in coming years they'll become the largest single cost category despite the fact that specialty drugs serve a minority of the population. For those dependent on these drugs, HealthPocket's analysis found that comparing premiums and annual caps on out-of-pocket costs is often more important than comparing health plans' copayments and co-insurance fees for drugs."
...of an invention disclosed and ‎claimed in the [reference] patent," the later expiring patent ‎is invalid for obviousness-type double patenting. But "the nonclaim portion of the earlier patent ‎ordinarily does not qualify as prior art against the pa‎tentee."

More Content

All (233) | News (196) | Reports (0) | Blogs (36) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
The Most Interesting Man Revolutionizing The He... [Published Forbes.com - Aug 30 2014]
AbbVie: Growth Story Or Patent Expiration Night... [Published BioPortfolio - Aug 28 2014]
AbbVie: Growth Story Or Patent Expiration Night... [Published Seeking Alpha - Aug 28 2014]
5 Things Express Scripts' Management Wants You ... [Published Motley Fool Discussion Boards - Aug 28 2014]
Insurance Insider NewsBrokers Are Failing Their... [Published California Broker Magazine - Aug 28 2014]
Is It Time to Buy AbbVie Stock? [Published Motley Fool Discussion Boards - Aug 27 2014]
Western drugmakers try to shop their way out of... [Published Nikkei Asian Review - Aug 27 2014]
2015 Platinum Plans Are Best Buy for Consumers ... [Published Tamar Securities - Aug 26 2014]
Recent patent cases from the Federal Circuit - ... [Published Lexology - Aug 26 2014]
PsA Outcomes Linked to Adalimumab Levels, Antib... [Published Diabetes Care - Aug 26 2014]
Five things for pharma marketers to know: Monda... [Published Medical Marketing And Media - Aug 25 2014]
Psoriatic arthritis outcomes worse with smoking [Published The Clinical Advisor - Aug 25 2014]
Humira patent invalid for obviousness type doub... [Published Lexology - Aug 25 2014]
Strange Bedfellows: PDLI Fuses Dividends With B... [Published InvestorPlace.com - Aug 25 2014]
Burger King may buy Tim Hortons [Published Buffalo News - Aug 25 2014]
Wegmans offers specialty pharmacy services in a... [Published Individual.com - Aug 25 2014]
5 Step Psoriasis Action Plan [Published HealthNewsDigest.com - Aug 25 2014]
Biotech comeback [Published Insurance News Net - Aug 22 2014]
Eli Lilly Announces Successful Phase III Result... [Published Bidness Etc - Aug 22 2014]
Finnegan Beats Humira IP Licensing Claims for A... [Published Law.com - Newswire - Aug 22 2014]
Biosimilar Interchangeability Problems Pose Com... [Published Regulatory Affairs Professionals Society - Aug 22 2014]
Lilly takes on Amgen's Enbrel [Published Medical Marketing And Media - Aug 21 2014]
Report: Payers Exert Cost Controls on High-Cost... [Published PT Community - Aug 21 2014]
Payers exert cost controls on high-cost biologi... [Published Pharma Letter - Aug 21 2014]
elevated AST/ALT readings [Published HealthBoards - Aug 21 2014]
Get the right drug to treat psoriasis [Published Consumer Reports - Aug 20 2014]
Payers Exert Cost Controls on High-Cost Biologi... [Published Securities Technology Monitor - Aug 20 2014]
Dermira Raises $51M to Advance Therapy for Psor... [Published Dow Jones Financial Information Services - Aug 19 2014]
Wegmans Now Offering Specialty Pharmacy Service... [Published Pharmacy Times - Aug 19 2014]
A New Cannabinoid-based Arthritis Therapy in th... [Published PredictWallStreet - Aug 19 2014]
1 2 3 4 5 6 7 8
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
elevated AST/ALT readings [Published HealthBoards - Aug 21 2014]
First post on here! My AST and ALT readings have been elevated for at least the past 3 years. My prior PCP did little blood testing so it may be more than 3 years. Today's results are ALT 55 and AST 59. I'm 57, have RA, hypothyroidism and bipolar ...
Biological Drugs Market Will Reach USD 2, 87,13... [Published PR.com Press Releases - Aug 19 2014]
New York, NY, August 19, 2014 --( PR.com )-- Persistence Market Research (http://www.persistencemarketresearch.com) Released New Market Report on "Global Market Study on Biological Drugs: North America to Witness Highest Growth by 2020” the global biological ...
Coherus' CHS-1420 meets primary endpoint in piv... [Published PBR - News - Aug 15 2014]
Coherus BioSciences has announced that CHS-1420, its proposed biosimilar of adalimumab (Humira), met the primary endpoint in a pivotal clinical pharmacokinetic (PK) similarity study that compared CHS-1420 to Humira in healthy subjects. ...
Coherus Announces CHS-1420 (Investigational Ada... [Published PR Newswire: Health - Aug 14 2014]
REDWOOD CITY, Calif., Aug. 14, 2014 /PRNewswire/ -- Coherus BioSciences, Inc. ("Coherus") today announced that CHS-1420, its proposed biosimilar of adalimumab (Humira®), met the primary endpoint in a pivotal clinical pharmacokinetic (PK) similarity ...
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Aug 04 2014]
1 2 3 4 5 6 7 8
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.